+34 679 490 537info@nanbiosis.com

Nanbiosis

U10. Drug Formulation

Ciber bbn

U10. Drug Formulation

  • Scientific Director: Prof. José Luis Pedraz joseluis.pedraz@ehu.es
  • Scientific Coordinator: Dr. Jesús Ciriza Astrain jeciriza@gmail.com
  • Entities: Universidad del País Vasco (UPV/EHU)
  • Address: Pharmacy & Pharmac. Technology Lab.; Facultad de Farmacia, C/Paseo de la Universidad 7, 01006 Vitoria-Gasteiz (Spain)
  • Phone: +34 945 013091
  • Fax: +34 945 013040
  • Web: NANOBIOCEL UPV/EHU

UPV-EHU

Order request

Description

Located at the Faculty of Pharmacy, University of the Basque Country (UPV), Campus of Vitoria, is led by Prof. José Luis Pedraz and consists of large laboratories for: cell culture, chromatography equipment, sample preparation and characterization and one specific for scale preparation of pharmaceutical formulations. This Unit has the capacity to design and evaluate dosage forms both classical and new dosage forms of biotech drugs, DNA, RNA and vaccines using different methodologies based on micro and nano-medicine. The latter methodology based on the microencapsulation of cells, peptides, proteins, and in general of biotech products, as well as the development and design of non-viral vectors for gene therapy, is one of the biggest singularities of this unit. It counts with the most advanced equipment for micro and nano encapsulation.

The aim of the Unit is to determine experimentally all the variables needed to develop an optimal formulation and work instructions for preparing final pharmaceutical products.

The pharmaceutical technology applied to drug development involves the selection of materials and procedures that can be adapted to different processes that lead to specific pharmaceutical forms. To do that, the Unit counts with the most advanced equipment to cover the development for all the steps of the process.

One of the singularities of this Units is that is GLP certified by the Spanish Medicament Agency

U10. Services & Rates

News U10

20 Jun

NANBIOSIS working on the development of next generation catheters

NANBIOSIS’ partners CIBER-BBN and JUMISC, with another 44 European partners, led by Philips Electronics Nederland B.V, will work on the development of next genration catheters.  The project, Position-II  (Ref. n. 783132), that pretends to diversify the production of smart catheters (overcoming the obsolescence of current ones), improve their performance (facilitating their use to be smaller), [...]

03 Jun

DRIVE Project: Artificial Biopancreas for Type I Diabetics

On Saturday, June 2, in the auditorium of the Artium museum in Vitoria, a meeting was held for patients with diabetes, organized by the group of European researchers of the DRIVE project with the aim of conecting patiens with researchers. The event was organized by the NanoBioCel research group of the CIBER-BBN and the University of [...]

28 May

New frontiers in the treatment of Diabetes type 1

On Saturday, June 2, at 10.30 in the auditorium of the Artium Museum in Vitoria-Gasteiz, a meeting will take place for patients with diabetes, organized by the group of European researchers of the DRIVE project. The objective of the meeting, held for the first time in Spain, is to connect researchers with all those with [...]

15 May

Nanotechnology, gene therapy, omics therapies and ‘big data’

Nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the Forum on Emerging Technologies oganized on May 8 by nanotechnology, gene therapy, omics therapies and ‘big data’ were the topics discussed in the I Forum on Emerging Technologies held on May 8, organized by the CIBER Internationalization Platform, of which the CIBERER, [...]

05 May

Gene therapy in pseudohypoparathyroidism

In 1942, Albright and colleagues described the first hormone resistance syndrome, which they called pseudohypoparathyroidism (PHP) (1), patients had a specific phenotype consisting of short stature, central obesity, round face, short neck and brachydactyly, which is what that today we know like Albright Hereditary Osteodystrophy (AHO, Albright Hereditary Osteodystrophy). Nanobiocel research group, coordinator of NANBIOSIS U10. [...]

30 Apr

I Forum on Emerging Technologies organized by CIBER

On May 8th, will take place in Madrid, at the Assembly Hall Ernest Lluch of the Instituto de Salud Carlos III, organized by CIBER Internationalization Platform (CIBER-BBN, CIBERER, CIBERES) the I Forum on Emerging Technologies. The objective of this meeting is to promote the exchange of ideas and scientific knowledge among the CIBER research groups with the [...]

02 Mar

NANBIOSIS Unit 10 of Drug Formulation participates in the European Project Position II

Nanobiocel, the CIBER-BNN – UPV-EHU group, led by José Luis Pedraz, Scientific Director of NANBIOSIS-ICTS U10 “Drug Formulation Unit” participates in the Position II European project, coordinated by Philips Electronics Nederland. The project, funded through the Horizon 2020 call with a global budget of more than 50 million euros, will be developed during three years [...]

23 Feb

NANBIOSIS ICTS invites groups and companies to discuss Smart Biomaterials and devices for Drug Delivery

On February 22nd, the National School of Health of the Carlos III Health Institute hosted the forum on Smart Biomaterials and biomedical devices for applications in drug delivery and regenerative medicine, organized by the ICTS Nanbiosis, an infrastructure shared by the CIBER-BBN and the Center of Minimally Invasive Surgery Jesus Usón (CCMIJU). This is the [...]

25 Jan

Cryopreservation of stem cells

Scientific Reports of the Nature Publications Group has recently published the article ‘Cryopreservation of human mesenchymal stem cells in an allogeneic bioscaffold based on platelet rich plasma and synovial fluid’. This research is part of the doctoral thesis of Haritz Gurruchaga, belonging to the NanoBioCel group of CIBER-BBN and UPV / EHU, which is focused [...]

25 Jan

Therapeutic approaches with CRISPR for albinism

Preclinical Development of CRISPR- based non-viral therapeutic approaches in existing cellular and animal models of Albinism, (NanoCripsAlbino Therapy)  is a multidiciplinar project to study ways to bring genetic editing tools to target cells to develop therapeutic strategies that can be used to treatment. The project, participated by Lluís Montoliu (CIBERER) and José Luis Pedraz (CIBER-BBN) [...]

U10-Drug Formulation
Read More

U11. Pharmaceutical Lab

JUMISC

U11. Pharmaceutical Lab

  • Scientific Coordinator: Dr. Francisco M. Sánchez Margallo msanchez@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

The pharmaceutical laboratory is enabled and equipped to store, formulate and reconstitute trial products for differents in vivo preclinical studies carried out by Nanbiosis with strict ISO 9001 quality standards and Good Laboratory Practice (GLP)

U11-Pharmaceutical Lab
Read More

U19. Clinical tests lab

JUMISC

U19. Clinical tests lab

Order request

Description

The clinical analysis laboratory performs a wide variety of analysis, including: biochemistry, hematology, coagulation, urinalysis, blood gases analysis, different biomarkers,… in various animal species (rat, mouse, rabbit, pig, sheep, dog, cat). All types of blood, urine and other body fluids tests can be analysed. The laboratory is certified with ISO-9001 and Good laboratory practices (GLP), these strict quality standards allow the production of high accuracy results. Species specific methodologies are used in each animal species according to their physiological and pathological identity.

Services

 

FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE

U19. Services & Rates
U19-CLINICAL TESTS LAB
Read More

U21. Experimental operating rooms

JUMISC

U21. Experimental operating rooms

  • Scientific Director: Dr. Francisco M. Sánchez Margallo msanchez@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

Experimental operating rooms with high technology and high field instrumentation to promote methodological and translational research class in Biomedicine, both minimally invasive surgery and new procedures and in preclinical development for technical evaluation, medical devices, biomaterials, etc. Surgical facilities allow the development and use of small and large animal models for research and experimental surgery in several longitudinal areas: cardiovascular diseases, liver and digestive diseases, respiratory and systemic diseases, endocrinology and urology, gynecological and reproductive diseases, pediatric diseases, orthopedics and traumatology, ophthalmology and experimental surgery in all organ systems have the infrastructure for transplant development, implants, prosthesis, biomaterials, etc. under high quality experimental conditions that allow surgery, clinical follow up and obtaining biological samples in these models.

U21. Experimental operating rooms
Read More

U22. Animal housing

JUMISC

U22. Animal housing

  • Scientific Director: Luis Dávila Gómez ldavila@ccmijesususon.com
  • Entities: Jesus Uson Minimally Invasive Surgery Centre (JUMISC)
  • Address: Carretera N-521, km 41, 10071 Cáceres
  • Phone: + 34 927 181 032
  • Web: JUMISC

Order request

Description

The JUMISC Animal Housing Unit provides services to companies and research groups in many preclinical trials. This unit advises designs and conducts preclinical validation on demand. It has qualified professionals to design, monitor and validate any type of biomedical study. In addition this unit has been certified by the Spanish Agency of Medicines and Health Products (AEMPS) for studies in “Dosing of test substance and non-clinical specimen drawing” and “Biocompatibility studies of medical devices”. These two new certifications are attached to existing “in vivo toxicity”, “Tolerance” and “Pharmacodynamics”. All these certifications allow NANBIOSIS members to perform studies to verify the effectiveness, safety and biocompatibility of nanotechnology under development. A most singular fact makes this unit is the possibility of housing, maintaining and supervising large animals for preclinical validations. This Service has extensive experience in handling and care of minipigs and what it entails use in preclinical studies.

Its perimeter area is 3,200 m2, and the net floor area is 2,865 m2. It has large rooms to house the experimental animals according to their species characteristics (age, sex, weight, breed) and to the research projects they are assigned to. Among the equipment and facilities include: rooms for the maintenance of large animals, rooms for maintaining small ruminants, barrier zone for maintenance of rodents under SPF conditions, integrated operating room within the barrier area, multi-use rooms for rodents and lagomorphs maintenance, room for receipt and handling of animals, quarantine rooms pre-experimental process, room to perform small procedures and cures and preparation rooms for large animals prior to the surgical area.

This unit has facilities with a perimeter area of 3,200 m2 and it has large rooms to house the experimental animals according to their species characteristics.

Unit 22. Services & Rates
U22-Animal housing
Read More